LimmaTech Biologics
Latest round
- Series A
Last raised
- Feb 2024
Total raised
- $39M
Investors
- 4
About LimmaTech Biologics
a. LimmaTech, operates as a biopharmaceutical company that focuses on the development of vaccines against infections caused by antimicrobial resistance (AMR) and sexually transmitted diseases. As of August 2024, Franz-Werner Haas is the CEO of the company. The company leverages its proprietary vaccine technology platform, where it utilizes a genetically engineered E. coli strain to produce vaccine candidates in a single, scalable process.
Who invested in LimmaTech Biologics
4 investors across 2 rounds
See all investors in LimmaTech Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about LimmaTech Biologics
Who invested in LimmaTech Biologics?
LimmaTech Biologics has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has LimmaTech Biologics raised?
LimmaTech Biologics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did LimmaTech Biologics last raise money?
LimmaTech Biologics's most recent round on record is a Series A, in Feb 2024.
What does LimmaTech Biologics do?
LimmaTech Biologics is a biotechnology company.
Where is LimmaTech Biologics headquartered?
LimmaTech Biologics is headquartered in Zurich, Switzerland.
Which VCs invest in companies like LimmaTech Biologics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at LimmaTech Biologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like LimmaTech Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.